Skip to main content
OpenTrials
Completed

NCT Number: NCT01281202

Vigabatrin for the Treatment of Cocaine Dependency

The objective of this 26-28 week study is to demonstrate that the rate of cocaine dependent subjects treated with CPP-109 vigabatrin in addition to counseling, who completely stop use of cocaine in the last 2 weeks of the study's Treatment Phase (Weeks 8 and 9) will be higher than seen in subjects treated with placebo in addition to counseling.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Matrix Institute on Addictions, Los Angeles, California, United States

Loading trial locations.

About this study

The objective of this 26-28 week study is to demonstrate that the rate of cocaine dependent subjects treated with CPP-109 vigabatrin in addition to counseling, who completely stop use of cocaine in the last 2 weeks of the study's Treatment Phase (Weeks 8 and 9) will be higher than seen in subjects treated with placebo in addition to counseling.

There are 3 Phases to this study:

  • a 2-4 week Screening/Baseline Phase during which eligibility to be included in the trial will be tested;
  • a 9 week Treatment Phase during which subjects will receive CPP-109 or placebo tablets in addition to counseling; and
  • a 15 week Follow-up Phase, during the first 4 weeks (Weeks 10-13) of which subjects will continue to receive counseling.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able to understand the study and provide written informed consent.
  • Male or female at least 18 years of age.
  • Meet DSM-IV criteria for cocaine dependence as primary diagnosis, as determined by the Substance Abuse Structured Clinical Interview (SCID) for Diagnostic and Statistical Manual-IV (DSM-IV) module.
  • Have a verifiable place of primary residence.
  • Seeking treatment for cocaine dependence.
  • Be in generally good health based on history, physical examination, electrocardiogram, eye exam and laboratory findings.
  • If female of childbearing potential, use acceptable contraceptive methods (oral contraceptives (the pill), intrauterine device (IUD), contraceptive implants under the skin, contraceptive rings or patches or injections, diaphragms with spermicide, and condoms with spermicide). Surgical sterilization by tubal ligation or hysterectomy is acceptable.

Exclusion criteria

  • Please contact site for more information

Treatment and study plan

vigabatrin

Drug

Tablets

Other names: CPP-109, GVG, VGB

Matching Placebo

Drug

Tablets

Primary outcomes

  1. Abstinence

    Time frame: Weeks 8-9

    The number of subjects in each treatment group who are cocaine abstinent during the last 2 weeks of the Treatment Phase (Weeks 8 and 9).

Secondary outcomes

  1. Number of Participants With Cocaine Use

    Time frame: Week 3 - 9

Sponsors and collaborators

Lead sponsor

Catalyst Pharmaceuticals, Inc.

Industry

Collaborators

  • National Institute on Drug Abuse (NIDA)
  • VA Office of Research and Development

Registry information

Official study title

Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Jan 21, 2011
Registry last updated
May 18, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.